43 results
8-K
EX-99.1
VRDN
Viridian Therapeutics Inc
11 Mar 20
Miragen Reports Fourth Quarter and Full Year 2019 Financial Results
4:06pm
, miRagen presented data in preclinical studies testing remlarsen’s ability to penetrate injured corneas and reduce fibrosis after a corneal injury … . Topical administration of remlarsen to an injured rat cornea resulted in faster healing of the cornea and reduced scarring/hazing. Remlarsen has also
8-K
EX-99.1
VRDN
Viridian Therapeutics Inc
10 Jul 18
Miragen Therapeutics Announces Initiation of Phase 2 Clinical Trial OFMRG-201
7:15am
are benign growths that form when scar tissue grows excessively after skin is injured. The lesions can be disfiguring and are often itchy and painful
8-K
EX-99.1
VRDN
Viridian Therapeutics Inc
29 Apr 19
Miragen Therapeutics Announces New Data Supporting the Potential Use of Remlarsen
7:16am
in a more rapid restoration of epithelial thickness and a reduction in stromal thickness as compared to saline-treated injured eyes.
Remlarsen
8-K
EX-99.1
VRDN
Viridian Therapeutics Inc
8 May 19
Miragen Announces First Quarter 2019 Financial Results
4:01pm
in a more rapid restoration of epithelial thickness and a reduction in stromal thickness as compared to saline-treated injured eyes. Remlarsen treatment also
8-K
EX-99.1
VRDN
Viridian Therapeutics Inc
7 May 20
Miragen Reports First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
of remlarsen to an injured rat cornea resulted in faster healing of the cornea and reduced scarring/hazing. Remlarsen has also been observed in in vitro
8-K
EX-10.2
3a408m
17 Sep 20
Lee Rauch appointed President and CEO, following resignation by William Marshall
5:24pm